Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2022 results, Thursday 16 February
Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, will release its fourth quarter and second half 2022 results on Thursday, 16 February 2023 at 8am CEST. The results will be presented in a webcast with CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein at 2:30pm CEST.
We encourage you to send us questions in advance, to be addressed during the Q&A session. Please send your email to post@lytixbiopharma.com.
The presentation and subsequent Q&A session will be held in English and may be viewed live by registering here: https://forms.office.com/e/q06xRZSrBV
A recording of the presentation will be made available on https://www.lytixbiopharma.com/investors/overview.html after the presentation
For more information, please contact:
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
Ole Peter Nordby, Head of IR & Communication Manager: ole.peter.nordby@lytixbiopharma.com
About Lytix Biopharma AS
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient's immune system to fight cancer. The company's technology is based on pioneering research in 'host defense peptides' – nature's first line of defense towards foreign pathogens. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new and superior therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 targets cancer cells and disrupts their cell membranes, causing immunogenic cell death and release of a patient's tumor specific antigens and immune-stimulating molecules. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells.
For more information, visit www.lytixbiopharma.com.
Tags: